BioWorld MedTech

March 2, 2016

Nexstim facing uncertain future after stroke rehabilitation device trial fails

Nexstim Plc faces an uncertain future with its Navigated Brain Therapy (NBT) for stroke rehabilitation after a phase III study of the device failed to meet its primary endpoint. Read More

In releasing list of outstanding devices, China is promoting its med-tech sector

FDA posts September 2015 warning letter to Rewalk for 522 study

Savara so good: Aerovanc inhaled vancomycin nears pivotal with $20M series C

FDA decisions on Neuro-Spinal Scaffold propel Invivo's INSPIRE study, stock forward

Financings

Appointments & advancements

Daily M&A

Other news to note

Product briefs

Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026